
Index

A

- 3t3 protocol, 304–5
- Adaptors, 18, 22, 49, 125
- Agonists, 104, 207
- Antagonists, 207
- Antibodies, 74, 114, 136, 141, 143, 203, 205, 209, 233, 245–6, 248–9, 251–2, 254–6, 260–1, 263–6, 287–290, 313, 316–7, 330, 343
 - monoclonal antibodies (MAb), 203, 205, 233, 245–9, 254–6, 287, 289–290, 313, 316–7
 - human anti-murine immunoglobulin antibodies, 246
 - phospho-specific antibodies, 260–261, 263, 265
 - polyclonal antibodies, 233, 246–7, 252, 287, 290, 313
 - single chain antibodies, 203
- Apoptosis, 24, 36, 82, 84, 87, 102–5, 255, 280, 282, 312
 - cell death, 87, 154–5, 215
- Assays, 24, 91, 110, 113–4, 135–6, 140–6, 210, 216, 221–2, 234, 237, 254–5, 260–4, 266–8, 288, 290–293, 304, 307, 312, 315–6. *See also kinases*
 - [³H] thymidine incorporation assay, 312
 - apoptosis assays, 254–5
 - assay for anchorage independent growth of cells in soft agar, 291–3, 304, 307
 - colony formation assay, 312, 315–6
 - colony-PCR assay, 24
 - ELISA, 250–1, 253–4
 - FACS analysis, 254
 - guanine nucleotide exchange assay, 290–1

- hanging drop technique, 339–340
- immune complex kinase assays, 263–264, 266–268, 288. *See also Kinases*

- AKT, 261–262, 266–267
- internalization assays, 254
- microarray assays. *See microarrays*
- RT-PCR assays, 113. *See also PCR*
- transformation assays, 304, 307
- transfection assays, 110

- Atomic force microscopy, 153, 155
- ATP, 8–9, 18, 24, 259–262, 267–268, 278, 288
 - ³²P ATP, 8–9, 18, 24, 259–262, 267–268, 288

B

- Bacterial artificial chromosomes (BACs), 153–161, 181
 - BAC transfection, 153–161
 - generation of stable lines by BAC transfection, 157, 160
 - BAC DNA preparation, 156, 158
 - BAC cotransfection, 157, 160
- Bioinformatics, 81–2, 85
- Biological display system, 203
- Biopanning, 205–7, 209–210

C

- Cancer, 16, 34–6, 67, 69–71, 76, 81–2, 87, 102, 107, 109–111, 125, 165–6, 176, 178, 183, 187, 229, 237, 245–9, 253, 264, 303, 321. *See also cell cycle; cell lines; cellular transformation; chemoprevention; chemoresistance; chemotherapy; genes; genome; kinase; immunotherapy; microarray;*

- molecular cytogenetics; nude mice; tumors; viral therapy*
 breast cancer, 34, 247
 carcinogenesis, 102, 107, 110
 carcinoma, 34–5, 82, 87, 229, 246–9, 264
 chromosome aberrations, 16, 71, 76, 82, 165–6, 176, 178, 183, 187
 colorectal cancer, 248
 hybridoma, 237, 246–8, 253
 leukemia, 70–1, 103–5, 107, 113, 246
 lymphoma, 70–1, 82, 246
 pancreatic cancer, 35–6
 prostate cancer, 34, 125, 248–9
 prostate carcinoma tumor antigen (PCTA)-1, 125
 prostate tumor inducing gene (PTI)-1, 248
 prostatic intraductal neoplasia (PIN), 249
 therapy, 36, 111, 183, 245–7, 303
 cDNA, 2–9, 18, 21–4, 26, 32–3, 36, 48–50, 67–8, 74, 90–3, 107, 113–4, 123–5, 127, 155, 208, 234, 247.
See also sequences
 cDNA libraries, 3–7, 9, 16–18, 21–24, 42, 45, 124–5, 203, 205, 221, 235, 247, 251
 digestion, cDNA, 4–5, 18, 22–3, 49, 51, 54–5
 ditags, 49, 51–57
 hybridization, 8, 18, 23–4, 34, 72, 74, 91
 isolation, 107, 113
 labeling/labeled, cDNA, 32, 37, 91
 ligation, cDNA, 3, 6, 22–3, 49–50, 57
 preparation, cDNA, 5, 48, 127
 purification, cDNA, 127, 236
 Cell cycle, 84, 87, 107, 110, 115, 156, 176, 312–3, 316
 BrdU (5-Bromo-2'-deoxyuridine), 312–313, 316
 cell division, 156, 176
 Cyclin D1, 107, 110, 115. *See also Chemoprevention*
 proliferation, 156, 291, 303–4, 311–2
 Cell lines
 bacterial cells, 203
 BHK (baby hamster kidney), 293, 295–296
 bone marrow stromal cells (BMSC), 35
 CHOC 400, 154–5
 COLO-357 pancreatic cells, 35–6
 CREF-Trans 6 (rat embryo fibroblast target cell), 247–248, 251
 dormant/non-tumorigenic (D-HEp3), 229, 237–8
 HCT116 (colon carcinoma), 264
 HNSCC (head and neck squamous carcinomas), 87, 89, 93
 human bronchial epithelial (HBE) cells, 107–110, 113–114
 human melanoma cells, 18–19
 human squamous carcinoma cells (Human SCC), 91, 229. *See also dormant/non-tumorigenic (D-HEp3)*
 keratinocytes, 85, 87–9, 91, 93
 LNCaP (human prostate), 248–9
 Mammalian cells, 153–5, 203, 220, 222, 277, 280, 282, 286, 288–290, 292, 294, 304
 MCF-7 (human breast carcinoma), 247
 MEF (mouse embryonic fibroblast), 91, 303–8, 311–2, 314–7
 growth of, 91
 Murine SCC, 82, 85, 87–8, 90–1
 NB4 APL, 104–5
 NB4-S1 APL, 107, 113–4
 NIH 3T3, 280
 osteosarcoma Saos-2, 154–5
 Pam 212, 82, 85, 90–1, 93
 rodent hepatocytes, 264
 yeast cells, 203, 220, 280
 Cellular immortalization, 107, 109, 116, 304, 312, 321–322
 Cell isolation, 312, 314
 Cellular senescence, 247, 304, 311–312

Cellular transformation, 23, 63, 71, 76–7, 83, 85, 107–8, 165, 220–1, 248, 279, 283, 303–4, 311–312

Checkpoint, 280, 282–3, 312. *See also kinases; eIF; cell cycle*

Chemoprevention, 102–104, 106–111; *See also cancer; cancer therapy; chemoresistance; chemotherapy; tumor marker, Cyclin D1, 110*

Chemoresistance, 36, 227–8

Chemotherapy, 227
chemotherapeutic agents, 36
cytotoxicity, 155

Chick embryo chorioallantoic membrane (CAM) system, 230–231, 237–8

Chromatin, 103, 135–6, 141, 153.
See also microarray; chromatin immunoprecipitation (ChIP) assay

Cleavage, 49–51, 141, 187

Cloning. *See Gene Cloning*

Cluster analysis, 83, 85–8, 92

CpG, 187–190

Cytokines. *See Interferons (IFNs)*

D

Data mining, 33, 75

Differentiation, 18, 35, 71, 87, 102–4, 106–107, 247, 312

DNA, 5–9, 21–3, 31–2, 34, 36–7, 48–9, 57–8, 62–4, 67, 84, 102, 107, 113, 136, 140, 142–6, 154–6, 158–160, 166, 170, 172–3, 175, 179, 181–2, 188–96, 204–5, 215–6, 219–220, 236, 247–8, 251, 279, 285–290, 293, 306.
See also sequences

DNA-binding domains (DBD), 216

DNA methylation. *See also Genomic bisulfate sequencing, 187–96*

DNA synthesis, 4, 21, 48–9, 68, 72, 74, 125, 127, 316
first strand cDNA synthesis, 4, 21, 48, 125, 127
second strand cDNA synthesis, 5, 21, 48–9, 125, 127

isolation, 5, 136, 158, 172
labeled/labeling, 172, 181
nucleotide (oligonucleotide), 44–5, 68, 74–5, 124, 170, 172, 189, 204, 312
preparation, 156, 158, 167, 172
purification, 154, 172
sequences, 170, 181

Driver, 3–6, 9, 16–18, 21–23, 246–247, 251–253. *See cDNA; cDNA libraries; Surface-Epitope Masking*

E

E.coli, 5, 48–9, 209–210, 236

Electrophoresis, 24, 32, 49, 61–4, 73, 142, 190, 255, 260–261, 264, 284, 287–289
SDS-PAGE, 260–261, 264, 266–268, 284, 287–290

Embryo, 104, 230, 237–8, 242, 247, 303, 311–2, 314. *See also cell lines; MEF (mouse embryonic fibroblast)*

ERK 1/2, 229, 262–263, 266–268.
See also Kinases

Ethidium bromide dot quantitation, 63–4

Expressed sequence tags (EST), 41, 90.
See also gene cloning; sequences

G

Genes, 15–9, 21, 23–4, 32–7, 41–2, 44, 67–72, 75–77, 81–3, 85, 87, 92–3, 102–7, 115, 123, 125, 153–161, 187–191, 196–7, 204, 216, 229–230, 235, 237–8, 247–9, 278, 280, 303.
See also gene expression; differentially expressed genes; gene cloning; gene profiling; gene ontology and promoter analysis

AEG-1 (Astrocyte-elevated gene-1), 125

B-Raf, 268

class predictor, 70–1, 76

Drosophilila tolloid gene, 34

Human bone morphogenetic protein (BMP)-1 gene, 34

- Human polynucleotide phosphorylase (hPNPase^{old-35}), 125, 317
- Interferon-stimulated genes (ISGs), 109–111, 113, 125
- mda-5* (Melanoma differentiation associated gene-5), 125
- mda-7/IL-24* (melanoma differentiation-associated gene 7/interleukin-24), 279
- mda-9* (Melanoma differentiation associated gene-9/syntenin), 125
- oncogenes, 247, 303–4, 306, 312
- p53, 155, 279, 304
- PEGen-28 (Progression elevated gene-28), 125
- PEGen-28 (Progression elevated gene-42), 125
- p-glycoprotein, multidrug resistance surface expressed (MDR-1), 245, 247, 251
- PKR, 278–9
- Ras, 304
- Rb, 304
- signature genes, 70–1, 76–7
- Thioredoxin-1 (TRX), 35–6
- transforming growth factor (TGF)-B, 35
- tumor suppressor genes, 187–8
- Gene cloning, 1–3, 9, 16, 18, 23–4, 31–2, 123–5, 205, 247, 251, 253
- pZero, 62–3
- rapid expression cloning system (RExCS), 247–8, 251
- Gene expression, 1–3, 8–9, 15–18, 24, 31, 34–36, 41–2, 67–71, 73–7, 81–3, 85, 87, 92–3, 101, 104–110, 114, 135–6, 153–6, 229, 236–8, 251, 279–280, 293, 303–4
- differentially-expressed genes, 1–3, 5–9, 23–4, 31–2, 34, 72, 77, 87, 92–3, 135, 229
- differential displays, 3–4, 6, 31–6
- differential display reverse transcription, 32
- differential RNA display (DDRT-PCR), 1–3. *See also PCR*
- reciprocal subtraction differential RNA display (RSDD), 3, 6, 16
- restriction fragment display, 35
- differential screening, 3, 16, 18. *See also microarrays*
- gene ontology and promoter analysis, 92–3, 95
- gene profiling, 34–35, 67–71, 73, 76, 85, 101, 104, 106–109, 123, 136, 153–5, 229–235, 322
- Serial Analysis of Gene Expression (SAGE), 41–46, 60–1
- test colony PCR, 60
- scale up colony PCR, 60–1
- SAGE 2000, 43
- reverse SAGE technique, 44
- long-SAGE, 44–5
- sage tag mapping, 43–4
- Gene profiling. *See also gene expression*
- identification, 1–3, 16, 18–9, 33–4, 42, 71, 76–77, 82–3, 87, 106, 165, 176, 249
- ribonomic profiling (ribonomics), 229–235. *See also assays; mRNA*
- unsupervised analysis, 68
- supervised analysis, 68
- mRNA expression profiling, 101
- Gene regulation, 1, 3, 33–5, 82–5, 87, 102, 105–7, 110, 153–4, 229–230, 237–8, 247, 259, 278, 280, 282, 304, 312
- down regulation, 3, 35, 85, 238
- upregulation, 3, 35, 82–3, 85, 87, 237–8, 280
- Genetic engineering, 246–7, 337
- Genome, 15, 41–2, 44, 67–8, 81–2, 87, 92–3, 123–4, 154, 166, 170–2, 176, 183, 204, 337
- cancer genome, 42, 166, 170–1
- human genome, 15, 44, 81, 123–4, 183, 337
- murine genome, 81–2, 87, 92–3

syngeneic murine model, 82, 87
 murine tumor progression model,
 87, 92–93

Genomic bisulfite sequencing, 188–193
 bisulfate sequence analysis and
 restriction analysis (bisulfate
 restriction analysis), 189
 methylation-sensitive single nucleotide
 primer extension, 189–190

ERMA (enzymatic regional methyl-
 ation assay), 190
 nonselective amplification, 188
 methylation-selective
 amplification, 188
 MSP (methylation specific PCR),
 188, 190–2, 194
 NMSP (nested methylation specific
 PCR), 188, 191, 195–197

H

Histones, 103, 135–6, 146, 313, 317

I

Imaging, digital, 75, 170–1, 175, 177,
 179, 183
 Fluorescence, 32, 91–2, 170–1, 179,
 183, 191, 254–255, 261

Immunoblotting, 110, 114, 236, 255,
 259, 262–6, 287, 289–290

Immunochemistry, 255

Immunodeficiency, 34, 304

Immunohistochemistry, 77, 255–6

Immunological subtraction, *See Surface-
 Epitope Masking (SEM)*

Immunoprecipitation (IP), 136, 141–4,
 229, 232–3, 259–261, 263–4, 266–8,
 287–8

Immunopurification, 231, 234, 287–8

Immunotherapy, 71. *See also antibodies;
 cancer; cancer therapy; nude mice;
 tumors; Surface-Epitope Masking
 (SEM)*

Interferons (IFNs), 277–278, 280, 282–3.
Also cytokines

K

Kinases, 259–265, 266–268, 277–281,
 288–290, 322. *See also Assays*
 GCN2 (yeast kinase), 280–1
 eIF (eukaryotic translation
 initiation factor), 277, 279–283,
 285–6, 288–291

HRI (heme-regulated inhibitor
 kinase), 280

interferon-induced gene (*ISG-56*),
 125. *See also Genes,
 interferon-induced gene*

JNK, 262–263, 266–267

MEK 1, 268

p38 MAPK, 229–230, 235, 238, 258,
 263, 266–7
 ERK/p38 ratio, 229
 p38-hnRNP A1 pathway, 229–230
 p38 mitogen activated protein
 kinase (MAPK), 263, 266

PKR (double-stranded RNA-dependent
 protein kinase), 277–283, 286–289

Raf-1, 268

L

Lysates, 140–1, 143, 231–233, 260, 266,
 287, 290, 321–3, 325–6
 protein, 325
 tissue, 321–3, 325–6

M

Mice, 248, 252, 256, 304, 307–8
 immunocompetent, 251, 253, 279,
 282, 303–4
 nude, 280, 304

Microarray, 16, 41–2, 74–5, 81–3, 85, 87,
 89–90, 93, 104–8, 110, 114, 136, 146,
 183, 191, 321–322, 326, 328–332
 cDNA microarray, 16, 67–8, 82, 85,
 87, 89–90

microarray assay, 135–6, 140–6. *See
 also gene expression.*

chromatin immunoprecipitation
 (ChIP) assay, 135–6, 140–6.

- See also immunoprecipitation; chromatin*
- microarray expression analysis, 101, 104–7, 110
- genome microarray, 42, 322
- high density expression array, 42, 68
- human cDNA microarray, 90
- immunostaining microarray, 324, 329–330
- microarray printing, 326–327, 329
- microarray spot analysis, 325
- murine cDNA microarray, 89
- oligonucleotide micarray, 67–8, 82–3, 85, 87
- protein microarray, 105, 321–323
- Molecular cytogenetics, 165–183
- comparative genomic hybridization (CGH), 166–171. *See also gene expression; genome*
- labeled DNA Probes for CGH, preparation of, 166–169, 172–176
- conventional cytogenetic analysis, 166
- fluorescence in situ hybridization (FISH), 165, 179–183
- tumor chromosome preparations for FISH, 169, 176
- labeled DNA probes for FISH, 169
- spectral karyotype (SKY), 165, 169
- tumor chromosome preparations for SKY, 169, 176
- spectral karyotyping, 169–170, 176–179
- Human lymphocyte Metaphase Chromosomes, preparation of, 166, 171
- mRNA, 2, 4, 16–8, 21, 24, 32, 34, 44–7, 104–7, 124, 155, 229, 233–4. *See also sequences*
- binding, 47–8
- digestion, 17
- hybridization, 37, 67
- litigation, 18
- mRNA-protein complexes (mRNP), 229, 233
- purification, 21, 72
- N**
- Northern blotting, 2, 4, 8–9, 18, 24, 42, 36–7, 113–4
- reverse Northern blotting, 4, 8–9, 18, 24
- Nuclear factor (NF)-*k*B, 81–2, 85, 87, 91, 93
- O**
- Oncolysis, 282–3
- P**
- PCR, 2–3, 6, 16, 18, 22–24, 33, 45, 50, 52–4, 60, 113, 123–5, 128, 136, 141–2, 145, 188–92, 194–5, 197–8. *See also gene expression, differential displays*
- Phages, 4–5, 203–5, 207–211. *See also gene expression*
- bacteriophages, 4–5, 204
- display, 203–5, 207–8, 210
- helper phage, 5, 204, 209
- phage display peptide libraries, 204–5, 207–9
- lytic phage, 205
- phagemid, 5, 204
- Plasmid, 4, 6–7, 90–1, 104, 115, 153–6, 181, 189, 204, 216, 220–2, 231, 235–6, 251, 261, 286, 293. *See also cDNA*
- Primers, 2, 6–7, 16, 18, 32–3, 36–7, 60–1, 64, 124–7, 128, 136, 142, 188–191, 192, 194, 196, 197, 231. *See also cDNA*
- Principle component analysis (PCA), 92
- Promoters, 135–6, 146, 154–155, 187
- Proteins, 34–6, 84–5, 93, 104–7, 110, 136, 140–1, 143–5, 154–5, 203–5, 207–8, 215–6, 220–2, 228–9, 231–4, 236–7, 247, 255, 259–261, 263–8, 278–280, 282, 286–7, 321–2, 325–6, 329–330,

337–9. *See also* microarray; chromatin immunoprecipitation (ChIP) assay
 amino acids, 203, 205, 207, 218–9, 260, 278, 282
 crystallization, 337–340
 ER stress, 282
 expression, 77, 105, 107, 155, 247, 286–7
 Messenger RNA-binding proteins (mRBPs), 229
 mRNA-protein complexes (mRNPs), 229, 233
 peptides, 33, 71, 203, 205, 207–8, 210–1, 260, 267, 326
 phosphorylation, 82, 85, 259–261, 265, 267–268, 278–282, 286, 289–290, 313, 322
 synthesis, 104, 280–2, 286
 UPR (Unfolded Protein Response), 282

R

Rapid Amplification of cDNA Ends (RACE), 123–5. *See also* PCR
 Tdt-mediated addition, 124
 RNA ligation-mediated protocol, 124–5
 SMART protocol, 125
 Complete Open Reading Frame (C-ORF) Technique, 123, 125
 dSLAP (degenerate stem and loop annealing primer), 125, 127
 Rapid Subtraction Hybridization (RaSH)
See Subtraction hybridization
 Recombination, 4, 154, 282–3, 286–8, 293, 312
 Retinoids, 102–111, 115. *See also* chemoprevention; proteins
 retinoic acid (RA), 105–110, 113–4
 retinoic acid response element (RARE), 104
 nuclear receptors, 102–3
 target genes, 103–111, 115
 RIP 140 (Receptor interacting protein 140), 104–106

tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 18, 104–6
 UBE1L, 106–107, 110–1, 113, 115
 Ribonomics. *See* gene profiling; mRNA
 RNA, 3–4, 16, 21, 32, 34, 36–7, 44, 46–7, 67–8, 73–4, 76, 91, 113–4, 228, 229–230, 231–3, 234–6, 237, 238.
See also gene expression; microarray; mRNA; sequences
 RNA-binding Protein (RBP),
 RNA interference (RNAi), 229
 isolation, 2–4, 21, 34, 36–7, 46–8, 73–4, 91, 114, 234
 RNA, Short hairpin (shRNA), 229–231, 235–238
 gene targeting, 231
 gene silencing, 229, 235
 functional analysis of, 238
 Robotics, 36

S

Sequences, 2, 4, 16, 32–4, 41–2, 44–5, 61, 74–5, 82, 85, 93, 123–5, 146, 170, 179, 181, 183, 187–191, 205, 207, 216, 231, 236, 248, 260, 279, 337.
See also expressed sequence tag; SAGE
 amino acid, 34, 205, 207, 260, 337
 cDNA, 2, 123–4
 DNA, 170, 179, 181, 187–8, 190, 216, 248
 genome, 42, 44, 170, 183
 mRNA, 42, 124
 nucleic acid, 179
 peptide, 205, 207
 phage, 205
 plasmid, 4
 primer, 16, 32–3, 191
 promoter, 146, 187
 RNA, 179, 279
 shRNA, 231, 236
 Sequencing, 31, 33, 37, 41–2, 44, 61, 128, 188–191, 204–5, 237 *See also* genomic bisulfate sequencing

Southern blot analysis, 187–8
 Stem cells, 247, 251, 312
 Subtraction hybridization, 3–4, 6, 16–19, 34
 differential RNA display, 16
 rapid subtraction hybridization (RaSH), 16–19, 21
 representational differential analysis (RDA), 16, 18
 reciprocal subtraction differential RNA display (RSDD), 3–4, 6–7, 16
 RNA fingerprinting by arbitrary primed PCR, 16, 32
 suppression subtractive hybridization (SSH), 16, 18
 Surface-epitope masking, 245–246, 248, 251–256. *See also antibodies*

T

Tester, 3–6, 9, 16–18, 21–23, 247–248, 251–252. *See Surface-Epitope Masking; cDNA; cDNA libraries*
 Transfection, 87–91, 115, 154–161, 236, 248, 289, 293, 306, 312
 LipofectamineJ 2000, 155, 157, 159–160, 223, 305, 306
 Transcription, 2–3, 8, 17, 21, 32, 34–5, 37, 90–1, 102–5, 107, 110, 124–5, 127, 135–6, 146, 153, 216, 278
 reverse transcription, 2–3, 8, 17, 21, 37, 91, 124–5, 127
 reverse transcriptase (RT-PCR), 32
 transcriptional activation domain (AD), 216
 Tumors, 16, 18–9, 34, 36, 67, 69–73, 75–7, 81–2, 87–93, 102–5, 107, 110, 165–6, 170, 172, 176, 178, 183, 187, 191, 227–9, 235–8, 245–8, 251–2, 255, 264, 280, 282–3, 291, 303–4, 307–8. *See also cancer; chemoprevention; chemoresistance; chemotherapy; immunotherapy; mice; nude mice; viral therapy*
 dormancy, 227–230, 235–7

formation, 304
 growth/progression, 8, 17, 18–9, 21, 36, 37, 82–3, 85, 87–91, 93, 101, 165, 235, 238, 247, 280, 291, 303
 malignancy, 35, 71, 73, 76–7, 81–2, 101–2, 279
 B-cell malignancy, 71, 77
 lymphoma, 82
 squamous cell carcinoma (SCC), 82, 87–8, 90–1
 metastasis, 19, 82–3, 85, 88, 93, 101, 227, 247
 molecular classification, 70, 75–6
 tumor associated antigens (TAAs), 245–6
 tumorigenesis, 280, 303–4, 307–8
 TUNEL (TdT-mediated dUTP nick end labeling) methods, 255
 Two-hybrid systems, 215–6, 220, 222. *See also assays*
 Mammalian two-hybrid system, 215, 222–224
 yeast two-hybrid system, 215, 220

V

Virus, 18, 34, 36, 156, 204, 278–280, 282–3, 293–6, 304–7, 311, infection, 18, 36, 279, 293–4, 304, 306–7
 replication, 156, 278–280, 283
 retrovirus, 304–7, 312
 therapy, 282
 VSV, 282–3, 293–296

W

Western Analysis, 113–4, 264
 enhanced chemiluminescence (ECL), 255. *See also proteins*

X

X-ray analysis, 207, 265, 337–8
 X-Ray crystallography, 207, 337
 X-ray diffraction, 338